Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association.
10.4093/dmj.2017.41.6.423
- Author:
Hyun Jin KIM
1
;
Seok O PARK
;
Seung Hyun KO
;
Sang Youl RHEE
;
Kyu Yeon HUR
;
Nan Hee KIM
;
Min Kyong MOON
;
Byung Wan LEE
;
Jin Hwa KIM
;
Kyung Mook CHOI
Author Information
1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.
- Publication Type:Practice Guideline ; Review
- Keywords:
Cardiovascular benefit;
Clinical practice guideline;
Combination therapy;
Glucagon-like peptide-1 receptor agonist;
Hypoglycemia;
Monotherapy
- MeSH:
Cardiovascular Diseases;
Diabetes Mellitus, Type 2*;
Glucagon-Like Peptide 1*;
Glucagon-Like Peptide-1 Receptor*;
Humans;
Hypoglycemia;
Hypoglycemic Agents;
Insulin;
Weight Loss
- From:Diabetes & Metabolism Journal
2017;41(6):423-429
- CountryRepublic of Korea
- Language:English
-
Abstract:
The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.
